Tissue plasminogen activator treatment of experimental subretinal hemorrhage
- PMID: 1899537
- DOI: 10.1016/s0002-9394(14)72259-7
Tissue plasminogen activator treatment of experimental subretinal hemorrhage
Abstract
To determine if tissue plasminogen activator, a clot-specific fibrinolytic agent, could eventually be used to assist in the clearance or removal of subretinal hemorrhage, we studied the effect of subretinal injections of tissue plasminogen activator, autologous blood, balanced salt solution, and the combination of either tissue plasminogen activator or balanced salt solution after subretinal injection of autologous blood on retinal morphologic characteristics and clearance of subretinal hemorrhage in the albino rabbit. No morphologic evidence of tissue plasminogen activator toxicity was found in the rabbit retina at a dose of 25 to 50 micrograms/0.1 ml. Subretinal hemorrhage cleared faster after subretinal injection of tissue plasminogen activator when compared to balanced salt solution (P = .0005) but did not completely prevent overlying retinal degeneration. Both tissue plasminogen activator and balanced salt solution were found to decrease the toxic effects of subretinal blood on the morphologic characteristics of the rabbit retina, and this effect can be explained at least partly by dilution of the subretinal blood.
Similar articles
-
Tissue plasminogen activator treatment of experimental subretinal hemorrhage.Retina. 1991;11(2):250-8. doi: 10.1097/00006982-199111020-00011. Retina. 1991. PMID: 1925092
-
Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage.Ophthalmology. 1992 Apr;99(4):515-21. doi: 10.1016/s0161-6420(92)31939-6. Ophthalmology. 1992. PMID: 1584568
-
A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.Am J Ophthalmol. 1999 Dec;128(6):739-46. doi: 10.1016/s0002-9394(99)00239-1. Am J Ophthalmol. 1999. PMID: 10612511
-
Treatment of subretinal hemorrhages with tissue plasminogen activator.Curr Opin Ophthalmol. 2001 Jun;12(3):207-11. doi: 10.1097/00055735-200106000-00011. Curr Opin Ophthalmol. 2001. PMID: 11389348 Review.
-
Subretinal hemorrhage.Int Ophthalmol Clin. 1995 Fall;35(4):95-104. Int Ophthalmol Clin. 1995. PMID: 8847196 Review. No abstract available.
Cited by
-
The use of tissue plasminogen activator in post-traumatic total hyphaema.Graefes Arch Clin Exp Ophthalmol. 1996 Jan;234(1):67-8. doi: 10.1007/BF00186522. Graefes Arch Clin Exp Ophthalmol. 1996. PMID: 8750854
-
The use of tissue plasminogen activator in postvitrectomy cases.Int Ophthalmol. 1993 Apr;17(2):95-100. doi: 10.1007/BF00942782. Int Ophthalmol. 1993. PMID: 8407122
-
Neurodegeneration, gliosis, and resolution of haemorrhage in neovascular age-related macular degeneration, a clinicopathologic correlation.Eye (Lond). 2021 Feb;35(2):548-558. doi: 10.1038/s41433-020-0896-y. Epub 2020 May 4. Eye (Lond). 2021. PMID: 32366998 Free PMC article.
-
Plasminogen activators promote excitotoxicity-induced retinal damage.FASEB J. 2005 Aug;19(10):1280-9. doi: 10.1096/fj.04-3403com. FASEB J. 2005. PMID: 16051695 Free PMC article.
-
Five-year Outcome of Aflibercept Administration with "Treat and Extend" for Neovascular Age-Related Macular Degeneration.Clin Ophthalmol. 2025 Mar 12;19:835-845. doi: 10.2147/OPTH.S501953. eCollection 2025. Clin Ophthalmol. 2025. PMID: 40092741 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources